According to the American Cancer Society, excluding skin cancer, colorectal cancer or bowel cancer is the third most common cancer diagnosed in both men and women in the United States. It is estimated that there will be 93,090 new cases of colon cancer and 39,610 new cases of rectal cancer in 2015.
Colorectal cancer starts in the large intestine. More than half of people are diagnosed in the later stages, requiring more complex treatment, with a poorer chance of survival. As with all types of cancer, the earlier bowel cancer is detected, the better the outcome for patients. Now, the scene is set for the entry of a simple, affordable blood test that can diagnose bowel cancer at the earliest possible stage. The research is being carried out by Randox Laboratories working with scientists at Dublin City University.
More sensitive and accurate than existing tests, this simple test will detect antibodies in the blood which are produced as the body reacts to the onset of bowel cancer. The study identifies very specific biomarkers, resulting in a test which is more sensitive and accurate than existing screening.
The new, quick and non-invasive blood test will also avoid the need for Faecal Occult Blood Test (FOBT) and will help avoid unnecessary and costly colonoscopies. According to a BBC report, the new blood test will be available by the end of 2016.
Involved in the research and development of innovative, high quality solutions to make diagnostic testing quicker with higher accuracy, Randox manufactures a wide range of lab equipment such as clinical chemistry reagents, clinical chemistry analyzers and multi-analyte controls and single analyte controls.